Citigroup upgraded DuPont (NYSE:DD) from Neutral to Buy in a statement released earlier today.
- Updated: October 3, 2016
Having a price of $66.97, DuPont (NYSE:DD) traded 1.25% higher on the day. With the last close up 1.89% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. DD has recorded a 50-day average of $68.46 and a two hundred day average of $66.56. Trade Volume was down over the average, with 513,473 shares of DD changing hands under the typical 2,681,120
Citigroup has upgraded DuPont (NYSE:DD) from Neutral to Buy in a statement released on 10/3/2016.
Recent Performance Chart
DuPont has P/E ratio of 26.97 with a 52 week low of $49.53 and a 52 week high of $75.72 and has a market cap of $0.
In addition to Citigroup reporting its stock price target, a total of 15 brokers have issued a report on the company. The average stock price target is $72.13 with 4 brokerages rating the stock a strong buy, 3 brokerages rating the stock a buy, 11 firms rating the stock a hold, 1 firm rating the stock a underperform, and finally 0 firms rating the stock a sell.
About DuPont (NYSE:DD)
E. I. du Pont de Nemours and Company (DuPont) is a science and technology-based company. The Company consists of over 10 businesses aggregated into six segments: Agriculture, Electronics & Communications, Industrial Biosciences, Nutrition & Health, Performance Materials and Safety & Protection. Its products include corn hybrids and soybean varieties, herbicides, fungicides and insecticides in Agriculture segment; photopolymers and electronic materials in Electronics & Communications segment; enzymes and bio-based materials in Industrial Biosciences segment; cultures, emulsifiers, texturants, natural sweeteners and soy-based food ingredients in Nutrition & Health segment; engineering polymers, packaging and industrial polymers, films and elastomers in Performance Materials segment, and nonwovens, aramids and solid surfaces in Safety & Protection segment. It is also involved in other businesses, such as pre-commercial programs, nonaligned businesses and pharmaceuticals in other.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.